Summit Therapeutics (SMMT) Net Margin (2017 - 2022)
Summit Therapeutics' (SMMT) quarterly Net Margin came in at 8014.55% in Q3 2022, down 651730.0% YoY from N/an in Q3 2021, and down 41.13% on a QoQ basis from 5678.72% in Q2 2022.
Summit Therapeutics (SMMT) Net Margin (2017 - 2022) Analysis & Trends
Summit Therapeutics (SMMT) has 6 years of Net Margin data on file, last reported at 8014.55% in Q3 2022.
- Quarterly Net Margin fell 651730.0% year-over-year to 8014.55% in Q3 2022, while the trailing twelve-month figure through Jun 2023 was 274831.82% (down 27079769.0% YoY) and the FY2022 annual result came in at 11174.75%, down 627691.0% from the prior year.
- Net Margin fell to 8014.55% in Q3 2022, from 5678.72% in the prior quarter.
- In the past five years, Net Margin ranged from a high of 86.93% in Q4 2019 to a low of 42835.09% in Q2 2021.
- A 5-year average of 6600.8% and a median of 4988.73% in 2019 frame the typical range for Net Margin.
- Annual changes were most pronounced in 2021 — Net Margin plunged 3384744 bps — and 2022, when it jumped 3715636 bps.
- Tracing SMMT's Net Margin over 5 years: stood at 1205.04% in 2018, then soared by 107 bps to 86.93% in 2019, then sank by 8520 bps to 7319.46% in 2020, then slumped by 48 bps to 10796.41% in 2021, then increased by 26 bps to 8014.55% in 2022.
- The last three Net Margin figures came in at 8014.55% (Q3 2022), 5678.72% (Q2 2022), and 8982.0% (Q1 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | -8,014.55% |
| Jun 30, 2022 | -5,678.72% |
| Mar 31, 2022 | -8,982.00% |
| Dec 31, 2021 | -10,796.41% |
| Sep 30, 2021 | -1,497.25% |
| Jun 30, 2021 | -42,835.09% |
| Mar 31, 2021 | -9,108.33% |
| Dec 31, 2020 | -7,319.46% |
| Sep 30, 2020 | -9,802.76% |
| Jun 30, 2020 | -8,987.65% |
| Mar 31, 2020 | -1,953.26% |
| Dec 31, 2019 | 86.93% |
| Oct 31, 2019 | -5,669.35% |
| Sep 30, 2019 | -4,308.11% |
| Jul 31, 2019 | -4,094.44% |
| Mar 31, 2019 | -1,423.47% |
| Oct 31, 2018 | -1,205.04% |
| Jul 31, 2018 | 70.17% |
| Apr 30, 2018 | -150.80% |
| Jan 31, 2018 | -346.40% |